Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma

Br J Haematol. 2014 Nov;167(4):563-5. doi: 10.1111/bjh.13004. Epub 2014 Jun 30.

Authors

Craig B Reeder¹, Donna E Reece, Vishal Kukreti, Joseph R Mikhael, Christine Chen, Suzanne Trudel, Kristina Laumann, Harjot Vohra, Rafael Fonseca, P Leif Bergsagel, Jose F Leis, Rodger Tiedemann, A Keith Stewart

Affiliation

¹ Hematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA. reeder.craig@mayo.edu.

PMID: 24974945
DOI: 10.1111/bjh.13004

No abstract available

Keywords: bortezomib; cyclophosphamide; myeloma; survival.

Publication types

Clinical Trial, Phase II
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Boronic Acids / administration & dosage
Boronic Acids / adverse effects
Bortezomib
Cyclophosphamide / administration & dosage
Cyclophosphamide / adverse effects
Dexamethasone / administration & dosage
Dexamethasone / adverse effects
Disease-Free Survival
Female
Humans
Male
Middle Aged
Multiple Myeloma / drug therapy*
Multiple Myeloma / mortality*
Pyrazines / administration & dosage
Pyrazines / adverse effects
Survival Rate

Substances

Boronic Acids
Pyrazines
Bortezomib
Dexamethasone
Cyclophosphamide